Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Other Accumulated Expenses (2018 - 2025)

Zevra Therapeutics' Other Accumulated Expenses history spans 9 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 39.73% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.4 million, down 39.73%, while the annual FY2025 figure was $1.4 million, 39.73% down from the prior year.
  • Other Accumulated Expenses reached $1.4 million in Q4 2025 per ZVRA's latest filing, down from $9.0 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $9.0 million in Q3 2025 to a low of $7000.0 in Q1 2022.
  • Average Other Accumulated Expenses over 5 years is $2.1 million, with a median of $1.3 million recorded in 2022.
  • Peak YoY movement for Other Accumulated Expenses: surged 1001.67% in 2021, then tumbled 98.08% in 2022.
  • A 5-year view of Other Accumulated Expenses shows it stood at $509000.0 in 2021, then grew by 23.58% to $629000.0 in 2022, then skyrocketed by 301.27% to $2.5 million in 2023, then decreased by 10.46% to $2.3 million in 2024, then crashed by 39.73% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Other Accumulated Expenses are $1.4 million (Q4 2025), $9.0 million (Q3 2025), and $6.9 million (Q2 2025).